A gas consumed dissolved in water, released from a tablet, or inhaled. In people with metabolic disease, fatty liver or inflammatory arthritis, controlled trials show small improvements in blood fats, blood sugar control, liver measures and body composition, and less effort felt during exercise. Where values are normal, very little moves. Hazards belong to the equipment, not the gas. (Full Review)
| Marker | Target | Why |
|---|---|---|
| LDL-C | Below 80 mg/dL | Primary demonstrated benefit |
| Total cholesterol | 140–200 mg/dL | The endpoint with the largest pooled effect |
| HDL-C | Above 55 mg/dL (men), above 65 mg/dL (women) | Detects the small pooled decrease flagged as a risk |
| Triglycerides | Below 80 mg/dL | Moves with metabolic response |
| HbA1c | 4.8–5.3% | Twenty-four-week metabolic endpoint |
| Fasting glucose | 75–86 mg/dL | Short-term glycaemic response |
| hs-CRP | Below 0.5 mg/L | Tracks the inflammatory pathway hydrogen is proposed to suppress |
| ALT | 10–26 U/L (men), 10–19 U/L (women) | Hepatic benefit and hepatic safety in one test |
| AST | Below 26 U/L | Fell 10% in the fatty liver trial |
| Serum potassium | 4.0–4.5 mmol/L | The one genuinely safety-critical test for electrolysis devices |
| eGFR | Above 90 mL/min/1.73 m² | Determines whether high-pH water is safe at all |
| Serum magnesium | 2.0–2.4 mg/dL | Tracks the load from tablet generators |
| Hepatic fat fraction | No established target; track change from the individual's own baseline | Direct measure of the outcome the fatty liver trial moved |
| Dissolved hydrogen in the prepared water | 1–15 ppm at the point of drinking | Confirms the intervention is actually being delivered |
Cadence: Baseline panel before starting; serum potassium and eGFR repeated at 4 weeks with a high-pH device or a potassium-retaining medication; full panel at 12 weeks, again at 24 weeks, and every 6–12 months thereafter.